The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
STABILITY
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
1 other identifier
interventional
15,828
38 countries
629
Brief Summary
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Dec 2008
Longer than P75 for phase_3
629 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 26, 2008
CompletedFirst Posted
Study publicly available on registry
December 1, 2008
CompletedStudy Start
First participant enrolled
December 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
October 17, 2013
CompletedResults Posted
Study results publicly available
August 10, 2017
CompletedAugust 10, 2017
March 1, 2017
4.8 years
November 26, 2008
July 12, 2017
July 12, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial Infarction [MI] or Non-fatal Stroke) During the Time Period for Follow-up of CV Events
CV death=death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting \>24 hours or results in death (in \<24 hours).
From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Secondary Outcomes (7)
Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events (Coronary Heart Disease [CHD] Death, Non-fatal MI, or Urgent Coronary Revascularization [CR] for MI) During the Time Period for Follow-up (FU) of CV Events
From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During Time Period for FU of CV Events
From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of Participants With CV Death During the Time Period for Follow-up of CV Events
From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of Participants With First Occurrence of MI (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events
From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
Number of Participants With First Occurrence of Stroke (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events
From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)
- +2 more secondary outcomes
Study Arms (2)
Darapladib
EXPERIMENTALSingle daily oral tablet
Placebo
PLACEBO COMPARATORSingle daily oral tablet
Interventions
Eligibility Criteria
You may qualify if:
- Men or women at least 18 years old. Women must be post-menopausal or using a highly effective method for avoidance of pregnancy.
- Current treatment with statin therapy unless the study doctor determines statins are not appropriate for the subject.
- Chronic coronary heart disease
- At least one of the following:
- At least 60 years old
- Diabetes requiring treatment with medication
- Low HDL cholesterol ("good cholesterol")
- Currently smoke cigarettes or stopped smoking within the past 3 months
- Diagnosed mild or moderate reduction in kidney function
- Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months prior to study entry) OR peripheral arterial disease.
You may not qualify if:
- Planned coronary revascularization (such as stent placement or heart bypass) or any other major surgical procedure.
- Liver disease
- Severe reduction in kidney function OR removal of a kidney OR kidney transplant
- Severe heart failure
- Blood pressure higher than normal despite lifestyle changes and treatment with medications
- Any life-threatening disease expected to result in death within the next 2 years (other than heart disease)
- Severe asthma that is poorly controlled with medication
- Pregnant (Note: A pregnancy test will be performed on all non-sterile women prior to study entry)
- Previous severe allergic response to food, drink, insect stings, etc.
- Drug or alcohol abuse within the past 6 months OR mental/psychological impairment that may prevent the subject from complying with study procedures or understanding the goal and potential risks of participating in the study.
- Certain medications that may interfere with the study medication (these will be identified by the study doctor)
- Participation in a study of an investigational medication within the past 30 days
- Current participation in a study of an investigational device
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- GlaxoSmithKlinelead
Study Sites (650)
GSK Investigational Site
Birmingham, Alabama, 35235, United States
GSK Investigational Site
Birmingham, Alabama, 35294-0007, United States
GSK Investigational Site
Huntsville, Alabama, 35801, United States
GSK Investigational Site
Anchorage, Alaska, 99508, United States
GSK Investigational Site
Little Rock, Arkansas, 72204, United States
GSK Investigational Site
Concord, California, 94520, United States
GSK Investigational Site
Lomita, California, 90717, United States
GSK Investigational Site
Los Angeles, California, 90024, United States
GSK Investigational Site
Los Angeles, California, 90036, United States
GSK Investigational Site
Madera, California, 93637, United States
GSK Investigational Site
Oakland, California, 94611, United States
GSK Investigational Site
Oakland, California, 94612, United States
GSK Investigational Site
Poway, California, 92064, United States
GSK Investigational Site
Sacramento, California, 95819, United States
GSK Investigational Site
San Diego, California, 92161, United States
GSK Investigational Site
San Ramon, California, 94582, United States
GSK Investigational Site
Santa Ana, California, 92705, United States
GSK Investigational Site
Spring Valley, California, 91978, United States
GSK Investigational Site
Thousand Oaks, California, 91360, United States
GSK Investigational Site
Colorado Springs, Colorado, 80920, United States
GSK Investigational Site
Denver, Colorado, 80218, United States
GSK Investigational Site
Golden, Colorado, 80401, United States
GSK Investigational Site
Thornton, Colorado, 80229, United States
GSK Investigational Site
Bridgeport, Connecticut, 06606, United States
GSK Investigational Site
Bridgeport, Connecticut, 06610, United States
GSK Investigational Site
Hartford, Connecticut, 06067, United States
GSK Investigational Site
Newark, Delaware, 19718, United States
GSK Investigational Site
Atlantis, Florida, 33462, United States
GSK Investigational Site
Gainesville, Florida, 32610, United States
GSK Investigational Site
Hollywood, Florida, 33023, United States
GSK Investigational Site
Jacksonville, Florida, 32207, United States
GSK Investigational Site
Jacksonville, Florida, 32216, United States
GSK Investigational Site
Jacksonville, Florida, 32258, United States
GSK Investigational Site
Jacksonville Beach, Florida, 32250, United States
GSK Investigational Site
Miami, Florida, 33136, United States
GSK Investigational Site
Miami, Florida, 33183, United States
GSK Investigational Site
Ocala, Florida, 34471, United States
GSK Investigational Site
Ponte Vedra Beach, Florida, 32081, United States
GSK Investigational Site
Conyers, Georgia, 30094, United States
GSK Investigational Site
Aurora, Illinois, 60504, United States
GSK Investigational Site
Chicago, Illinois, 60654, United States
GSK Investigational Site
Melrose Park, Illinois, 60160, United States
GSK Investigational Site
Avon, Indiana, 46123, United States
GSK Investigational Site
Franklin, Indiana, 46131, United States
GSK Investigational Site
Greenfield, Indiana, 46140, United States
GSK Investigational Site
Indianapolis, Indiana, 46256, United States
GSK Investigational Site
Indianapolis, Indiana, 46260, United States
GSK Investigational Site
Valparaiso, Indiana, 46383, United States
GSK Investigational Site
Iowa City, Iowa, 52242, United States
GSK Investigational Site
West Des Moines, Iowa, 50266, United States
GSK Investigational Site
Crestview Hills, Kentucky, 41017, United States
GSK Investigational Site
Louisville, Kentucky, 40206, United States
GSK Investigational Site
Louisville, Kentucky, 40213, United States
GSK Investigational Site
Lafayette, Louisiana, 70503, United States
GSK Investigational Site
New Iberia, Louisiana, 70563, United States
GSK Investigational Site
Slidell, Louisiana, 70458, United States
GSK Investigational Site
Auburn, Maine, 04210, United States
GSK Investigational Site
Bangor, Maine, 04401, United States
GSK Investigational Site
Scarborough, Maine, 04074, United States
GSK Investigational Site
Baltimore, Maryland, 21209, United States
GSK Investigational Site
Oxon Hill, Maryland, 20745, United States
GSK Investigational Site
Prince Frederick, Maryland, 20678, United States
GSK Investigational Site
Boston, Massachusetts, 02111, United States
GSK Investigational Site
Natick, Massachusetts, 01760, United States
GSK Investigational Site
Springfield, Massachusetts, 01103, United States
GSK Investigational Site
Cadillac, Michigan, 49601, United States
GSK Investigational Site
Detroit, Michigan, 48202, United States
GSK Investigational Site
Petoskey, Michigan, 49770, United States
GSK Investigational Site
Saint Cloud, Minnesota, 56303, United States
GSK Investigational Site
St Louis, Missouri, 63110, United States
GSK Investigational Site
Grand Island, Nebraska, 68803, United States
GSK Investigational Site
Las Vegas, Nevada, 89103, United States
GSK Investigational Site
Las Vegas, Nevada, 89130, United States
GSK Investigational Site
Browns Mills, New Jersey, 08015, United States
GSK Investigational Site
Elizabeth, New Jersey, 07202, United States
GSK Investigational Site
West Orange, New Jersey, 07052, United States
GSK Investigational Site
Albuquerque, New Mexico, 87102, United States
GSK Investigational Site
Buffalo, New York, 14215, United States
GSK Investigational Site
New York, New York, 10001, United States
GSK Investigational Site
New York, New York, 10016, United States
GSK Investigational Site
New York, New York, 10021, United States
GSK Investigational Site
Westfield, New York, 14787, United States
GSK Investigational Site
Williamsville, New York, 14221, United States
GSK Investigational Site
Charlotte, North Carolina, 28204, United States
GSK Investigational Site
Durham, North Carolina, 27710, United States
GSK Investigational Site
Gastonia, North Carolina, 28054, United States
GSK Investigational Site
Matthews, North Carolina, 28105, United States
GSK Investigational Site
Salisbury, North Carolina, 28144, United States
GSK Investigational Site
Statesville, North Carolina, 28677, United States
GSK Investigational Site
Wilmington, North Carolina, 28401, United States
GSK Investigational Site
Grand Forks, North Dakota, 58201, United States
GSK Investigational Site
Cincinnati, Ohio, 45227, United States
GSK Investigational Site
Cincinnati, Ohio, 45246, United States
GSK Investigational Site
Elyria, Ohio, 44035, United States
GSK Investigational Site
Garfield Heights, Ohio, 44125, United States
GSK Investigational Site
Kettering, Ohio, 45429, United States
GSK Investigational Site
Middleburg Heights, Ohio, 44130, United States
GSK Investigational Site
Sandusky, Ohio, 44870, United States
GSK Investigational Site
Toledo, Ohio, 43614, United States
GSK Investigational Site
Westlake, Ohio, 44145, United States
GSK Investigational Site
Oklahoma City, Oklahoma, 73120, United States
GSK Investigational Site
Portland, Oregon, 97219, United States
GSK Investigational Site
Beaver, Pennsylvania, 15009, United States
GSK Investigational Site
Danville, Pennsylvania, 17822-4201, United States
GSK Investigational Site
Doylestown, Pennsylvania, 18901, United States
GSK Investigational Site
Erie, Pennsylvania, 16502, United States
GSK Investigational Site
Jersey Shore, Pennsylvania, 17740, United States
GSK Investigational Site
Lewistown, Pennsylvania, 17044, United States
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site
Philipsburg, Pennsylvania, 16866, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, 15212, United States
GSK Investigational Site
Port Matilda, Pennsylvania, 16870, United States
GSK Investigational Site
Sayre, Pennsylvania, 18840, United States
GSK Investigational Site
Scranton, Pennsylvania, 18503, United States
GSK Investigational Site
Scranton, Pennsylvania, 18505, United States
GSK Investigational Site
Sellersville, Pennsylvania, 18960, United States
GSK Investigational Site
Wilkes-Barre, Pennsylvania, 18702, United States
GSK Investigational Site
York, Pennsylvania, 17403, United States
GSK Investigational Site
Providence, Rhode Island, 02904, United States
GSK Investigational Site
Charleston, South Carolina, 29401, United States
GSK Investigational Site
Charleston, South Carolina, 29425-6240, United States
GSK Investigational Site
Spartanburg, South Carolina, 29303, United States
GSK Investigational Site
Rapid City, South Dakota, 57701, United States
GSK Investigational Site
Sioux Falls, South Dakota, 57105, United States
GSK Investigational Site
Bristol, Tennessee, 37620, United States
GSK Investigational Site
Johnson City, Tennessee, 37601, United States
GSK Investigational Site
Amarillo, Texas, 79106, United States
GSK Investigational Site
Austin, Texas, 78705, United States
GSK Investigational Site
Corpus Christi, Texas, 78404, United States
GSK Investigational Site
Dallas, Texas, 75226, United States
GSK Investigational Site
Dallas, Texas, 75231, United States
GSK Investigational Site
Georgetown, Texas, 78626, United States
GSK Investigational Site
Harker Heights, Texas, 76548, United States
GSK Investigational Site
Houston, Texas, 77030, United States
GSK Investigational Site
Houston, Texas, 77081, United States
GSK Investigational Site
Plano, Texas, 75024, United States
GSK Investigational Site
San Antonio, Texas, 78217, United States
GSK Investigational Site
San Antonio, Texas, 78244, United States
GSK Investigational Site
Victoria, Texas, 77901, United States
GSK Investigational Site
Draper, Utah, 84020, United States
GSK Investigational Site
Burke, Virginia, 22015, United States
GSK Investigational Site
Norfolk, Virginia, 23502, United States
GSK Investigational Site
Richmond, Virginia, 23294, United States
GSK Investigational Site
Winchester, Virginia, 22601, United States
GSK Investigational Site
Kirkland, Washington, 98034, United States
GSK Investigational Site
Olympia, Washington, 98502, United States
GSK Investigational Site
Renton, Washington, 98057, United States
GSK Investigational Site
Seattle, Washington, 98104, United States
GSK Investigational Site
Spokane, Washington, 99204, United States
GSK Investigational Site
Spokane, Washington, 99207, United States
GSK Investigational Site
Spokane, Washington, 99208, United States
GSK Investigational Site
Tacoma, Washington, 98405, United States
GSK Investigational Site
Walla Walla, Washington, 99362, United States
GSK Investigational Site
Wenatchee, Washington, 98801, United States
GSK Investigational Site
Wausau, Wisconsin, 54401, United States
GSK Investigational Site
Adrogué, Buenos Aires, B1846DSK, Argentina
GSK Investigational Site
Bahía Blanca, Buenos Aires, B8000FTD, Argentina
GSK Investigational Site
CABA, Buenos Aires, C1124AAJ, Argentina
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1405BCH, Argentina
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1125ABD, Argentina
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1437JCP, Argentina
GSK Investigational Site
Junín, Buenos Aires, Argentina
GSK Investigational Site
La Plata, Buenos Aires, B1900AXI, Argentina
GSK Investigational Site
Mar del Plata, Buenos Aires, B7600FZN, Argentina
GSK Investigational Site
Ramos Mejía, Buenos Aires, B1704ETD, Argentina
GSK Investigational Site
Córdoba, Córdoba Province, X5000EPU, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, S2000CVD, Argentina
GSK Investigational Site
Buenos Aires, 1425, Argentina
GSK Investigational Site
Corrientes, W3400AMZ, Argentina
GSK Investigational Site
Corrientes, W3400CLH, Argentina
GSK Investigational Site
Mendoza, M5500CCG, Argentina
GSK Investigational Site
San Miguel de Tucumán, T4000ICL, Argentina
GSK Investigational Site
Santa Fe, 3000, Argentina
GSK Investigational Site
Garran, Australian Capital Territory, 2606, Australia
GSK Investigational Site
Coffs Harbour, New South Wales, 2450, Australia
GSK Investigational Site
Concord, New South Wales, 2139, Australia
GSK Investigational Site
Gosford, New South Wales, 2250, Australia
GSK Investigational Site
Liverpool, New South Wales, 2170, Australia
GSK Investigational Site
Auchenflower, Queensland, 4066, Australia
GSK Investigational Site
Kippa-Ring, Queensland, 4021, Australia
GSK Investigational Site
Sherwood, Queensland, 4075, Australia
GSK Investigational Site
Bedford Park, South Australia, 5042, Australia
GSK Investigational Site
Ballarat, Victoria, Australia
GSK Investigational Site
Caulfield South, Victoria, 3162, Australia
GSK Investigational Site
Frankston, Victoria, 3199, Australia
GSK Investigational Site
Malvern, Victoria, 3144, Australia
GSK Investigational Site
Fremantle, Western Australia, 6160, Australia
GSK Investigational Site
Joondalup, Western Australia, 6027, Australia
GSK Investigational Site
Nedlands, Western Australia, 6009, Australia
GSK Investigational Site
Aalst, 9300, Belgium
GSK Investigational Site
Antwerp, 2020, Belgium
GSK Investigational Site
Bonheiden, 2820, Belgium
GSK Investigational Site
Brussels, 1200, Belgium
GSK Investigational Site
Genk, 3600, Belgium
GSK Investigational Site
Hasselt, 3500, Belgium
GSK Investigational Site
La Louvière, 7100, Belgium
GSK Investigational Site
Leuven, 3000, Belgium
GSK Investigational Site
Liège, 4000, Belgium
GSK Investigational Site
Roeselaere, 8800, Belgium
GSK Investigational Site
Yvoir, 5530, Belgium
GSK Investigational Site
Salvador, Estado de Bahia, 41810010, Brazil
GSK Investigational Site
Goiânia, Goiás, 74605-050, Brazil
GSK Investigational Site
Belo Horizonte, Minas Gerais, 30150-221., Brazil
GSK Investigational Site
Belo Horizonte, Minas Gerais, 30380090, Brazil
GSK Investigational Site
Curitiba, Paraná, 80730150, Brazil
GSK Investigational Site
Natal, Rio Grande do Norte, 59020-100, Brazil
GSK Investigational Site
Pelotas, Rio Grande do Sul, 96015-290, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, 90610000, Brazil
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, 90880-480, Brazil
GSK Investigational Site
Campinas, São Paulo, 13059740, Brazil
GSK Investigational Site
São José do Rio Preto, São Paulo, 15015210, Brazil
GSK Investigational Site
São José do Rio Preto, São Paulo, 15090-000, Brazil
GSK Investigational Site
Rio de Janeiro, 20551-030, Brazil
GSK Investigational Site
São Paulo, 04012-909, Brazil
GSK Investigational Site
São Paulo, 04012180, Brazil
GSK Investigational Site
São Paulo, 05403-000, Brazil
GSK Investigational Site
São Paulo, 05403000, Brazil
GSK Investigational Site
Dimitrovgrad, 6400, Bulgaria
GSK Investigational Site
Pleven, 5800, Bulgaria
GSK Investigational Site
Plovdiv, 4003, Bulgaria
GSK Investigational Site
Rousse, 7002, Bulgaria
GSK Investigational Site
Sofia, 1000, Bulgaria
GSK Investigational Site
Sofia, 1233, Bulgaria
GSK Investigational Site
Sofia, 1431, Bulgaria
GSK Investigational Site
Sofia, 1527, Bulgaria
GSK Investigational Site
Sofia, 1606, Bulgaria
GSK Investigational Site
Veliko Tarnovo, 5000, Bulgaria
GSK Investigational Site
Edmonton, Alberta, T6G 2B7, Canada
GSK Investigational Site
Kelowna, British Columbia, V1Y 1E4, Canada
GSK Investigational Site
New Westminster, British Columbia, V3L 3W4, Canada
GSK Investigational Site
Surrey, British Columbia, V3V 1N1, Canada
GSK Investigational Site
Vancouver, British Columbia, V5Z 1M9, Canada
GSK Investigational Site
Victoria, British Columbia, V8R 4R2, Canada
GSK Investigational Site
Winnipeg, Manitoba, R2H 2A6, Canada
GSK Investigational Site
Bay Roberts, Newfoundland and Labrador, A0A 1G0, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
GSK Investigational Site
Halifax, Nova Scotia, B3H 3A7, Canada
GSK Investigational Site
Truro, Nova Scotia, B2N 1L2, Canada
GSK Investigational Site
Ajax, Ontario, L1S 7K8, Canada
GSK Investigational Site
Brampton, Ontario, L6Z 4N5, Canada
GSK Investigational Site
Hamilton, Ontario, L8L 2X2, Canada
GSK Investigational Site
Kitchener, Ontario, N2M 5N6, Canada
GSK Investigational Site
Mississauga, Ontario, L5B 2P7, Canada
GSK Investigational Site
Oshawa, Ontario, L1J 2J9, Canada
GSK Investigational Site
Ottawa, Ontario, K1Y 4W7, Canada
GSK Investigational Site
Scarborough Village, Ontario, M1E 5E9, Canada
GSK Investigational Site
Thornhill, Ontario, L4J 8L7, Canada
GSK Investigational Site
Toronto, Ontario, M3H 5S4, Canada
GSK Investigational Site
Toronto, Ontario, M4G 3E8, Canada
GSK Investigational Site
Toronto, Ontario, M5C 2T2, Canada
GSK Investigational Site
Gatineau, Quebec, J8Y 6S8, Canada
GSK Investigational Site
Greenfield Park, Quebec, J4V 2H1, Canada
GSK Investigational Site
Lévis, Quebec, G6V 4Z5, Canada
GSK Investigational Site
Montreal, Quebec, H1T 1C8, Canada
GSK Investigational Site
Montreal, Quebec, H1T 3Y7, Canada
GSK Investigational Site
Québec, Quebec, G1J 1Z6, Canada
GSK Investigational Site
Québec, Quebec, G1L 3L5, Canada
GSK Investigational Site
Saint-Charles-Borromée, Quebec, J6E 6J2, Canada
GSK Investigational Site
Sherbrooke, Quebec, J1J 2E3, Canada
GSK Investigational Site
Trois-Rivières, Quebec, G8T 7A1, Canada
GSK Investigational Site
Viña del Mar, Región de Valparaíso, Chile
GSK Investigational Site
Talcahuano, Región Del Biobio, 427 0918, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, 750 0922, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, 7500503, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, 7571831, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, 833 0074, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, 8360160, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, 8380456, Chile
GSK Investigational Site
Guangzhou, Guangdong, 510080, China
GSK Investigational Site
Nanjing, Jiangsu, 210029, China
GSK Investigational Site
Xi'an, Shaanxi, 710061, China
GSK Investigational Site
Jinan, Shandong, 250012, China
GSK Investigational Site
Hangzhou, Zhejiang, 310003, China
GSK Investigational Site
Beijing, 100034, China
GSK Investigational Site
Beijing, 100044, China
GSK Investigational Site
Beijing, 100730, China
GSK Investigational Site
Beijing, 100853, China
GSK Investigational Site
Guangzhou, 510100, China
GSK Investigational Site
Haerbin, 150001, China
GSK Investigational Site
Shanghai, 200032, China
GSK Investigational Site
Shanghai, 200040, China
GSK Investigational Site
Shanghai, 200127, China
GSK Investigational Site
Shanghai, 200233, China
GSK Investigational Site
Wuhan, 430022, China
GSK Investigational Site
Chomutov, 430 02, Czechia
GSK Investigational Site
Chrudim, 537 27, Czechia
GSK Investigational Site
Čáslav, 286 01, Czechia
GSK Investigational Site
Jihlava, 586 33, Czechia
GSK Investigational Site
Kladno, 272 80, Czechia
GSK Investigational Site
Kolín, 280 00, Czechia
GSK Investigational Site
Kroměříž, 767 55, Czechia
GSK Investigational Site
Milevsko, 399 01, Czechia
GSK Investigational Site
Písek, 397 01, Czechia
GSK Investigational Site
Prague, 128 08, Czechia
GSK Investigational Site
Příbram, 261 26, Czechia
GSK Investigational Site
Slaný, Czechia
GSK Investigational Site
Svitavy, 568 25, Czechia
GSK Investigational Site
Tábor, 390 03, Czechia
GSK Investigational Site
Ústí nad Orlicí, 562 18, Czechia
GSK Investigational Site
Aarhus, DK-8000, Denmark
GSK Investigational Site
Esbjerg, 6700, Denmark
GSK Investigational Site
Koebenhavn OE, 2100, Denmark
GSK Investigational Site
Silkeborg, 8600, Denmark
GSK Investigational Site
Tallinn, 1162, Estonia
GSK Investigational Site
Tallinn, 13419, Estonia
GSK Investigational Site
Tartu, 51014, Estonia
GSK Investigational Site
Aix-en-Provence, 13616, France
GSK Investigational Site
Avignon, 84082, France
GSK Investigational Site
Besançon, 25030, France
GSK Investigational Site
Bron, 69677, France
GSK Investigational Site
Créteil, 94010, France
GSK Investigational Site
Dijon, 21079, France
GSK Investigational Site
Lille, 59037, France
GSK Investigational Site
Marseille, 13385, France
GSK Investigational Site
Metz, 57085, France
GSK Investigational Site
Nantes, 44093, France
GSK Investigational Site
Narbonne, 11108, France
GSK Investigational Site
Nîmes, 30000, France
GSK Investigational Site
Paris, 75010, France
GSK Investigational Site
Paris, 75015, France
GSK Investigational Site
Paris, 75651, France
GSK Investigational Site
Paris, 75877, France
GSK Investigational Site
Pessac, 33604, France
GSK Investigational Site
Roubaix, 59056, France
GSK Investigational Site
Strasbourg, 67091, France
GSK Investigational Site
Toulouse, 31059, France
GSK Investigational Site
Tourcoing, 59208, France
GSK Investigational Site
Deggingen, Baden-Wurttemberg, 73326, Germany
GSK Investigational Site
Güglingen, Baden-Wurttemberg, 74363, Germany
GSK Investigational Site
Heidelberg, Baden-Wurttemberg, 69120, Germany
GSK Investigational Site
Ulm, Baden-Wurttemberg, 89081, Germany
GSK Investigational Site
Aschaffenburg, Bavaria, 63739, Germany
GSK Investigational Site
Haag, Bavaria, 83527, Germany
GSK Investigational Site
Höhenkirchen-Siegertsbrunn, Bavaria, 85635, Germany
GSK Investigational Site
Künzing, Bavaria, 94550, Germany
GSK Investigational Site
Munich, Bavaria, 80336, Germany
GSK Investigational Site
Mühldorf, Bavaria, 84453, Germany
GSK Investigational Site
Sulzbach-Rosenberg, Bavaria, 92237, Germany
GSK Investigational Site
Wallerfing, Bavaria, 94574, Germany
GSK Investigational Site
Bernau bei Berlin, Brandenburg, 16321, Germany
GSK Investigational Site
Frankfurt/M., Hesse, 60594, Germany
GSK Investigational Site
Kelkheim, Hesse, 65779, Germany
GSK Investigational Site
Hanover, Lower Saxony, 30625, Germany
GSK Investigational Site
Weyhe-Leeste, Lower Saxony, 28844, Germany
GSK Investigational Site
Bad Oeynhausen, North Rhine-Westphalia, 32545, Germany
GSK Investigational Site
Dorsten, North Rhine-Westphalia, 46282, Germany
GSK Investigational Site
Eschweiler, North Rhine-Westphalia, 52249, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, 45359, Germany
GSK Investigational Site
Goch, North Rhine-Westphalia, 47574, Germany
GSK Investigational Site
Herford, North Rhine-Westphalia, 32049, Germany
GSK Investigational Site
Lienen-Kattenvenne, North Rhine-Westphalia, 49536, Germany
GSK Investigational Site
Witten, North Rhine-Westphalia, 58455, Germany
GSK Investigational Site
Mainz, Rhineland-Palatinate, 55116, Germany
GSK Investigational Site
Rhaunen, Rhineland-Palatinate, 55624, Germany
GSK Investigational Site
Delitzsch, Saxony, 04509, Germany
GSK Investigational Site
Dresden, Saxony, 01307, Germany
GSK Investigational Site
Leipzg, Saxony, 04109, Germany
GSK Investigational Site
Leipzig, Saxony, 04315, Germany
GSK Investigational Site
Leipzig, Saxony, 04329, Germany
GSK Investigational Site
Schmiedeberg, Saxony, 01762, Germany
GSK Investigational Site
Magdeburg, Saxony-Anhalt, 39112, Germany
GSK Investigational Site
Berlin, 10367, Germany
GSK Investigational Site
Berlin, 10559, Germany
GSK Investigational Site
Berlin, 10787, Germany
GSK Investigational Site
Berlin, 12157, Germany
GSK Investigational Site
Berlin, 13055, Germany
GSK Investigational Site
Berlin, 13086, Germany
GSK Investigational Site
Berlin, 13125, Germany
GSK Investigational Site
Berlin, 13347, Germany
GSK Investigational Site
Berlin, 13353, Germany
GSK Investigational Site
Berlin, 13405, Germany
GSK Investigational Site
Hamburg, 22041, Germany
GSK Investigational Site
Agia Varvara, Athens, 123 51, Greece
GSK Investigational Site
Alexandroupoli, 68100, Greece
GSK Investigational Site
Athens, 11527, Greece
GSK Investigational Site
Athens, 124 62, Greece
GSK Investigational Site
Athens, 176 74, Greece
GSK Investigational Site
Chalcis, 341 00, Greece
GSK Investigational Site
Ioannina, 45500, Greece
GSK Investigational Site
Magoula, Elefsina, 192 00, Greece
GSK Investigational Site
Pátrai, 26 500, Greece
GSK Investigational Site
Thessaloniki, 546 42, Greece
GSK Investigational Site
Voula / Athens, 166 73, Greece
GSK Investigational Site
Hong Kong, Hong Kong
GSK Investigational Site
Shatin, New Territories, Hong Kong
GSK Investigational Site
Berettyóújfalu, Hungary
GSK Investigational Site
Budapest, 1032, Hungary
GSK Investigational Site
Budapest, 1033, Hungary
GSK Investigational Site
Budapest, 1096, Hungary
GSK Investigational Site
Esztergom, Hungary
GSK Investigational Site
Gyula, 5700, Hungary
GSK Investigational Site
Komárom, 2921, Hungary
GSK Investigational Site
Mosonmagyaróvár, 9200, Hungary
GSK Investigational Site
Sátoraljaújhely, 3980, Hungary
GSK Investigational Site
Székesfehérvár, 8000, Hungary
GSK Investigational Site
Szikszó, Hungary
GSK Investigational Site
Szolnok, 5004, Hungary
GSK Investigational Site
Ahmedabad, 380060, India
GSK Investigational Site
Bangalore, 560 099, India
GSK Investigational Site
Bangalore, 560034, India
GSK Investigational Site
Jaipur, 302001, India
GSK Investigational Site
Jaipur, 302017, India
GSK Investigational Site
Kochi, 683572, India
GSK Investigational Site
Mysore, 570020, India
GSK Investigational Site
New Delhi, 110060, India
GSK Investigational Site
Patiāla, 147001, India
GSK Investigational Site
Pune, 411004, India
GSK Investigational Site
Pune, 411030, India
GSK Investigational Site
Saket,Delhi, 110017, India
GSK Investigational Site
Vadodara, 390015, India
GSK Investigational Site
Vijayawada, 520008, India
GSK Investigational Site
Chieti, Abruzzo, 66013, Italy
GSK Investigational Site
Napoli, Campania, 80131, Italy
GSK Investigational Site
Carpi, Emilia-Romagna, 41012, Italy
GSK Investigational Site
Cona (Ferrara), Emilia-Romagna, 44124, Italy
GSK Investigational Site
Parma, Emilia-Romagna, 43100, Italy
GSK Investigational Site
Rome, Lazio, 00135, Italy
GSK Investigational Site
Milan, Lombardy, 20162, Italy
GSK Investigational Site
Cuneo, Piedmont, 12100, Italy
GSK Investigational Site
Novara, Piedmont, 28100, Italy
GSK Investigational Site
Ascoli Piceno, The Marches, 63100, Italy
GSK Investigational Site
Pisa, Tuscany, 56126, Italy
GSK Investigational Site
Treviso, Veneto, 31100, Italy
GSK Investigational Site
Aichi, 487-0013, Japan
GSK Investigational Site
Chiba, 270-2251, Japan
GSK Investigational Site
Fukuoka, 802-8555, Japan
GSK Investigational Site
Fukuoka, 811-3195, Japan
GSK Investigational Site
Fukuoka, 819-1104, Japan
GSK Investigational Site
Hokkaido, 063-0005, Japan
GSK Investigational Site
Hokkaido, 065-0033, Japan
GSK Investigational Site
Kagoshima, 892-0853, Japan
GSK Investigational Site
Kanagawa, 240-0116, Japan
GSK Investigational Site
Kanagawa, 247-8533, Japan
GSK Investigational Site
Kyoto, 611-0042, Japan
GSK Investigational Site
Nagano, 386-8610, Japan
GSK Investigational Site
Nagasaki, 856-8562, Japan
GSK Investigational Site
Nagasaki, 859-3615, Japan
GSK Investigational Site
Osaka, 574-0074, Japan
GSK Investigational Site
Ōita, 870-1133, Japan
GSK Investigational Site
Shiga, 520-2192, Japan
GSK Investigational Site
Shizuoka, 411-8611, Japan
GSK Investigational Site
Tokyo, 141-0001, Japan
GSK Investigational Site
Monterrey NL, Nuevo León, 64718, Mexico
GSK Investigational Site
Durango, 34080, Mexico
GSK Investigational Site
México, 10700, Mexico
GSK Investigational Site
México D.F,, 07760, Mexico
GSK Investigational Site
Amsterdam, 1105 AZ, Netherlands
GSK Investigational Site
Beverwijk, 1942 LE, Netherlands
GSK Investigational Site
Doetinchem, 7009 BL, Netherlands
GSK Investigational Site
Eindhoven, 5623 EJ, Netherlands
GSK Investigational Site
Enschede, 7513 ER, Netherlands
GSK Investigational Site
Goes, 4462 RA, Netherlands
GSK Investigational Site
Harderwijk, 3844 DG, Netherlands
GSK Investigational Site
Hoofddorp, 2134 TM, Netherlands
GSK Investigational Site
Leeuwarden, 8934 AD, Netherlands
GSK Investigational Site
Rotterdam, 3079 DZ, Netherlands
GSK Investigational Site
Sittard-geleen, 6162 BG, Netherlands
GSK Investigational Site
Sneek, 8601 ZK, Netherlands
GSK Investigational Site
The Hague, 2597 AX, Netherlands
GSK Investigational Site
Tiel, 4002 WP, Netherlands
GSK Investigational Site
Christchurch, New Zealand
GSK Investigational Site
Dunedin, New Zealand
GSK Investigational Site
Grafton, Auckland, 1030, New Zealand
GSK Investigational Site
Hamilton, 3204, New Zealand
GSK Investigational Site
Lower Hutt, New Zealand
GSK Investigational Site
Nelson, New Zealand
GSK Investigational Site
Otahuhu, Auckland, 1640, New Zealand
GSK Investigational Site
Palmerston North, 4410, New Zealand
GSK Investigational Site
Takapuna, Auckland, 0622, New Zealand
GSK Investigational Site
Tauranga, 3112, New Zealand
GSK Investigational Site
Timaru, 7910, New Zealand
GSK Investigational Site
Whangarei, New Zealand
GSK Investigational Site
Bergen, 5021, Norway
GSK Investigational Site
Moss, 1501, Norway
GSK Investigational Site
Oslo, 0160, Norway
GSK Investigational Site
Oslo, 0407, Norway
GSK Investigational Site
Karachi, 75510, Pakistan
GSK Investigational Site
Karachi, 75950, Pakistan
GSK Investigational Site
Korangi / Karachi, Pakistan
GSK Investigational Site
Lahore, 54000, Pakistan
GSK Investigational Site
Lahore, Pakistan
GSK Investigational Site
Multan, 60000, Pakistan
GSK Investigational Site
Rawalpindi Cantt, 46000, Pakistan
GSK Investigational Site
Jesus Maria, Lima region, Lima 11, Peru
GSK Investigational Site
Callao, Callao 2, Peru
GSK Investigational Site
Lima, Lima 11, Peru
GSK Investigational Site
Ermita, Manila, 1000, Philippines
GSK Investigational Site
Manila, 1000, Philippines
GSK Investigational Site
Manila, 1100, Philippines
GSK Investigational Site
Quezon City, 1109, Philippines
GSK Investigational Site
Quezon City, 1113, Philippines
GSK Investigational Site
Quezon City, Philippines
GSK Investigational Site
San Juan City, 1502, Philippines
GSK Investigational Site
Bydgoszcz, 85-079, Poland
GSK Investigational Site
Bydgoszcz, 85-435, Poland
GSK Investigational Site
Gdynia, 81-423, Poland
GSK Investigational Site
Kowanówko, Poland
GSK Investigational Site
Krakow, 31-202, Poland
GSK Investigational Site
Mielec, 39-300, Poland
GSK Investigational Site
Ostrów Wielkopolski, 63-400, Poland
GSK Investigational Site
Płońsk, 09 - 100, Poland
GSK Investigational Site
Radom, 26-617, Poland
GSK Investigational Site
Ruda Śląska, 41-706, Poland
GSK Investigational Site
Siemianowice Śląskie, 41-100, Poland
GSK Investigational Site
Skierniewice, Poland
GSK Investigational Site
Torun, 87-100, Poland
GSK Investigational Site
Tychy, 43-100, Poland
GSK Investigational Site
Warsaw, 03-285, Poland
GSK Investigational Site
Warsaw, 04-073, Poland
GSK Investigational Site
Wroclaw, 50-349, Poland
GSK Investigational Site
Włocławek, 87-800, Poland
GSK Investigational Site
Bucharest, 011461, Romania
GSK Investigational Site
Bucharest, 011601, Romania
GSK Investigational Site
Bucharest, 011794, Romania
GSK Investigational Site
Bucharest, 022328, Romania
GSK Investigational Site
Bucharest, 041915, Romania
GSK Investigational Site
Bucharest, 042122, Romania
GSK Investigational Site
Bucharest, 050098, Romania
GSK Investigational Site
Deva, 330084, Romania
GSK Investigational Site
Galati, 800087, Romania
GSK Investigational Site
Târgu Mureş, 540136, Romania
GSK Investigational Site
Kemerovo, 650002, Russia
GSK Investigational Site
Kemerovo, 650055, Russia
GSK Investigational Site
Moscow, 111020, Russia
GSK Investigational Site
Moscow, 111539, Russia
GSK Investigational Site
Moscow, 117292, Russia
GSK Investigational Site
Moscow, 119620, Russia
GSK Investigational Site
Moscow, 121 552, Russia
GSK Investigational Site
Moscow, 121552, Russia
GSK Investigational Site
Novosibirsk, 630003, Russia
GSK Investigational Site
Novosibirsk, 630008, Russia
GSK Investigational Site
Novosibirsk, 630047, Russia
GSK Investigational Site
Ryazan, 390026, Russia
GSK Investigational Site
S.-Petresburg, 195067, Russia
GSK Investigational Site
Saint Pertersburg, 196247, Russia
GSK Investigational Site
Saint Petersburg, 193312, Russia
GSK Investigational Site
Saint Petersburg, 195067, Russia
GSK Investigational Site
Saint Petersburg, 199106, Russia
GSK Investigational Site
St'Petersburg, 194156, Russia
GSK Investigational Site
Yekaterinburg, 620109, Russia
GSK Investigational Site
Yekaterinburg, 620144, Russia
GSK Investigational Site
Yekaterinburg, Russia
GSK Investigational Site
Bratislava, 813 69, Slovakia
GSK Investigational Site
Bratislava, 833 05, Slovakia
GSK Investigational Site
Košice, 040 22, Slovakia
GSK Investigational Site
Nitra, 949 01, Slovakia
GSK Investigational Site
Parktown, Gauteng, 2193, South Africa
GSK Investigational Site
Bellville, 7531, South Africa
GSK Investigational Site
Bloemfontein, 9301, South Africa
GSK Investigational Site
Kempton Park, 1619, South Africa
GSK Investigational Site
Kuils River, 7580, South Africa
GSK Investigational Site
Moreletapark, 0181, South Africa
GSK Investigational Site
Olivedale, 2188, South Africa
GSK Investigational Site
Paarl, 7646, South Africa
GSK Investigational Site
Parktown West, 2193, South Africa
GSK Investigational Site
Parow, 7505, South Africa
GSK Investigational Site
Pinelands, 7405, South Africa
GSK Investigational Site
Somerset West, 7130, South Africa
GSK Investigational Site
Soweto, 2013, South Africa
GSK Investigational Site
Umhlanga, 4319, South Africa
GSK Investigational Site
Cheongju-si, 361-711, South Korea
GSK Investigational Site
Daegu, 700-721, South Korea
GSK Investigational Site
Gangnam-gu, Seoul, 135-710, South Korea
GSK Investigational Site
Gwangju, 501-757, South Korea
GSK Investigational Site
Jeonju-si, Jeollabuk-Do, 561-712, South Korea
GSK Investigational Site
Seo-gu Busan, 602-739, South Korea
GSK Investigational Site
Seongnam-si Gyeonggi-do, 463-707, South Korea
GSK Investigational Site
Seoul, 110-744, South Korea
GSK Investigational Site
Seoul, 120-752, South Korea
GSK Investigational Site
Seoul, 130-702, South Korea
GSK Investigational Site
Seoul, 136-705, South Korea
GSK Investigational Site
Seoul, 137-701, South Korea
GSK Investigational Site
Seoul, 138-736, South Korea
GSK Investigational Site
Seoul, 143-729, South Korea
GSK Investigational Site
Uijeongbu-si Kyonggi-do, 480-717, South Korea
GSK Investigational Site
Alicante, 03114, Spain
GSK Investigational Site
Granada, 18012, Spain
GSK Investigational Site
Jerez de la Frontera, 11407, Spain
GSK Investigational Site
Madrid, 28029, Spain
GSK Investigational Site
Madrid, 28031, Spain
GSK Investigational Site
Madrid, 28034, Spain
GSK Investigational Site
Madrid, 28040, Spain
GSK Investigational Site
Madrid, 28041, Spain
GSK Investigational Site
Madrid, 28046, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Marid, 28040, Spain
GSK Investigational Site
Málaga, 29010, Spain
GSK Investigational Site
Oviedo, 33006, Spain
GSK Investigational Site
Pozuelo de Alarcón/Madrid, 28223, Spain
GSK Investigational Site
San Juan (Alicante), 03550, Spain
GSK Investigational Site
San Sebastián, 20014, Spain
GSK Investigational Site
San Sebastián de Los Reyes/Madrid, Spain
GSK Investigational Site
Santa Coloma de Gramanet (Barcelona), 08923, Spain
GSK Investigational Site
Santander, 39008, Spain
GSK Investigational Site
Seville, 41071, Spain
GSK Investigational Site
Valdemoro/Madrid, 28340, Spain
GSK Investigational Site
Eksjö, SE-575 36, Sweden
GSK Investigational Site
Gothenburg, SE-413 45, Sweden
GSK Investigational Site
Gothenburg, SE-416 85, Sweden
GSK Investigational Site
Linköping, SE-581 85, Sweden
GSK Investigational Site
Lund, SE-222 21, Sweden
GSK Investigational Site
Malmo, SE-205 02, Sweden
GSK Investigational Site
Östersund, SE-831 83, Sweden
GSK Investigational Site
Stockholm, SE-111 35, Sweden
GSK Investigational Site
Stockholm, SE-111 57, Sweden
GSK Investigational Site
Stockholm, SE-182 88, Sweden
GSK Investigational Site
Umeå, SE-901 85, Sweden
GSK Investigational Site
Uppsala, SE-751 85, Sweden
GSK Investigational Site
Västerås, SE-721 89, Sweden
GSK Investigational Site
Västervik, SE-593 81, Sweden
GSK Investigational Site
Changhua, 500, Taiwan
GSK Investigational Site
Taichung, 407, Taiwan
GSK Investigational Site
Tainan, 704, Taiwan
GSK Investigational Site
Taipei, 100, Taiwan
GSK Investigational Site
Taipei, 104, Taiwan
GSK Investigational Site
Taipei, 112, Taiwan
GSK Investigational Site
Bangkok, 10330, Thailand
GSK Investigational Site
Bangkok, 10400, Thailand
GSK Investigational Site
Bangkok, 10700, Thailand
GSK Investigational Site
Chiang Mai, 50200, Thailand
GSK Investigational Site
Donetsk, 83045, Ukraine
GSK Investigational Site
Kharkiv, 61002, Ukraine
GSK Investigational Site
Kharkiv, 61018, Ukraine
GSK Investigational Site
Kharkiv, 61037, Ukraine
GSK Investigational Site
Kharkiv, 61176, Ukraine
GSK Investigational Site
Kyiv, 02660, Ukraine
GSK Investigational Site
Kyiv, 03680, Ukraine
GSK Investigational Site
Kyiv, 04114, Ukraine
GSK Investigational Site
Lviv, 79044, Ukraine
GSK Investigational Site
Odesa, 65025, Ukraine
GSK Investigational Site
Odesa, 65114, Ukraine
GSK Investigational Site
Vinnytsia, 21029, Ukraine
GSK Investigational Site
Zaporizhzhia, 69118, Ukraine
GSK Investigational Site
Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
GSK Investigational Site
Glasgow, Lanarkshire, G11 6NT, United Kingdom
GSK Investigational Site
Motherwell, Lanarkshire, ML1 3JX, United Kingdom
GSK Investigational Site
Chelsea, London, SW3 6NP, United Kingdom
GSK Investigational Site
Liverpool, Merseyside, United Kingdom
GSK Investigational Site
Harrow, Middlesex, HA1 3UJ, United Kingdom
GSK Investigational Site
Chertsey, Surrey, KT16 0PZ, United Kingdom
GSK Investigational Site
Chichester, Sussex West, PO19 4SE, United Kingdom
GSK Investigational Site
Barnet, EN5 3DJ, United Kingdom
GSK Investigational Site
Coatbridge, ML5 3AP, United Kingdom
GSK Investigational Site
Cottingham, HU16 5JQ, United Kingdom
GSK Investigational Site
Cumbernauld, G67 1BJ, United Kingdom
GSK Investigational Site
Hamilton, ML3 8AA, United Kingdom
GSK Investigational Site
Hertfordshire, United Kingdom
GSK Investigational Site
Liverpool, L7 8XP, United Kingdom
GSK Investigational Site
Newcastle upon Tyne, NE7 7DN, United Kingdom
GSK Investigational Site
Paisley, PA2 9PN, United Kingdom
Related Publications (21)
Jiang W, Huang G, Du J, Yang H, Zhou S, Dai D, Tang K, Fang L, Wang X, Deng X. White blood cell counts can predict 4-year cardiovascular disease risk in patients with stable coronary heart disease: a prospective cohort study. Front Cardiovasc Med. 2024 Sep 26;11:1358378. doi: 10.3389/fcvm.2024.1358378. eCollection 2024.
PMID: 39390990DERIVEDSjolin K, Aulin J, Wallentin L, Eriksson N, Held C, Kultima K, Oldgren J, Burman J. Serum Neurofilament Light Chain in Patients With Atrial Fibrillation. J Am Heart Assoc. 2022 Jul 19;11(14):e025910. doi: 10.1161/JAHA.122.025910. Epub 2022 Jul 15.
PMID: 35861814DERIVEDHeld C, Hadziosmanovic N, Aylward PE, Hagstrom E, Hochman JS, Stewart RAH, White HD, Wallentin L. Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease - A STABILITY Substudy. J Am Heart Assoc. 2022 Feb;11(3):e023667. doi: 10.1161/JAHA.121.023667. Epub 2022 Jan 21.
PMID: 35060389DERIVEDSiddiqui MK, Smith G, St Jean P, Dawed AY, Bell S, Soto-Pedre E, Kennedy G, Carr F, Wallentin L, White H, Macphee CH, Waterworth D, Palmer CNA. Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events. Diabetologia. 2022 Jan;65(1):101-112. doi: 10.1007/s00125-021-05574-5. Epub 2021 Sep 25.
PMID: 34562103DERIVEDWallentin L, Eriksson N, Olszowka M, Grammer TB, Hagstrom E, Held C, Kleber ME, Koenig W, Marz W, Stewart RAH, White HD, Aberg M, Siegbahn A. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLoS Med. 2021 Jan 13;18(1):e1003513. doi: 10.1371/journal.pmed.1003513. eCollection 2021 Jan.
PMID: 33439866DERIVEDWhite HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, Linhart A, Pais P, Diaz R, Steg PG, Krug-Gourley S, Granger CB, Hochman JS, Koenig W, Harrington RA, Held C, Wallentin L; STABILITY Investigators. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. Am Heart J. 2020 Jul;225:97-107. doi: 10.1016/j.ahj.2020.04.004. Epub 2020 Apr 18.
PMID: 32480059DERIVEDHilvo M, Wallentin L, Ghukasyan Lakic T, Held C, Kauhanen D, Jylha A, Lindback J, Siegbahn A, Granger CB, Koenig W, Stewart RAH, White H, Laaksonen R; STABILITY Investigators. Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. J Am Heart Assoc. 2020 May 18;9(10):e015258. doi: 10.1161/JAHA.119.015258. Epub 2020 May 7.
PMID: 32375553DERIVEDStewart RAH, Held C, Krug-Gourley S, Waterworth D, Stebbins A, Chiswell K, Hagstrom E, Armstrong PW, Wallentin L, White H. Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2019 Apr 2;8(7):e010641. doi: 10.1161/JAHA.118.010641.
PMID: 30897999DERIVEDHeld C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Ostlund O, Wallentin L; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077.
PMID: 29066452DERIVEDHagstrom E, Norlund F, Stebbins A, Armstrong PW, Chiswell K, Granger CB, Lopez-Sendon J, Pella D, Soffer J, Sy R, Wallentin L, White HD, Stewart RAH, Held C. Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. J Intern Med. 2018 Jan;283(1):83-92. doi: 10.1111/joim.12692. Epub 2017 Oct 23.
PMID: 28960596DERIVEDGuimaraes PO, Granger CB, Stebbins A, Chiswell K, Held C, Hochman JS, Krug-Gourley S, Lonn E, Lopes RD, Stewart RAH, Vinereanu D, Wallentin L, White HD, Hagstrom E, Danchin N. Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Sep 14;6(9):e006695. doi: 10.1161/JAHA.117.006695.
PMID: 28912210DERIVEDStewart RAH, Hagstrom E, Held C, Wang TKM, Armstrong PW, Aylward PE, Cannon CP, Koenig W, Lopez-Sendon JL, Mohler ER 3rd, Hadziosmanovic N, Krug-Gourley S, Ramos Corrales MA, Siddique S, Steg PG, White HD, Wallentin L; STABILITY Investigators. Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2017 Aug 22;6(8):e006096. doi: 10.1161/JAHA.117.006096.
PMID: 28862971DERIVEDLindholm D, Lindback J, Armstrong PW, Budaj A, Cannon CP, Granger CB, Hagstrom E, Held C, Koenig W, Ostlund O, Stewart RAH, Soffer J, White HD, de Winter RJ, Steg PG, Siegbahn A, Kleber ME, Dressel A, Grammer TB, Marz W, Wallentin L. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol. 2017 Aug 15;70(7):813-826. doi: 10.1016/j.jacc.2017.06.030.
PMID: 28797349DERIVEDVedin O, Hagstrom E, Ostlund O, Avezum A, Budaj A, Flather MD, Harrington RA, Koenig W, Soffer J, Siegbahn A, Steg PG, Stewart RAH, Wallentin L, White HD, Held C; STABILITY Investigators. Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. Int J Cardiol. 2017 Oct 15;245:271-276. doi: 10.1016/j.ijcard.2017.07.036. Epub 2017 Jul 17.
PMID: 28735759DERIVEDHagstrom E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER 3rd, Steg PG, Tarka E, Ostlund O, White HD, Siegbahn A, Wallentin L; STABILITY Investigators. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clin Chem. 2017 Jan;63(1):325-333. doi: 10.1373/clinchem.2016.260570. Epub 2016 Nov 3.
PMID: 27811204DERIVEDWallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagstrom E, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Mohler ER 3rd, Siegbahn A, Tarka E, Steg PG, Stewart RA, Weiss R, Ostlund O, White HD; STABILITY Investigators. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016 Jun 21;5(6):e003407. doi: 10.1161/JAHA.116.003407.
PMID: 27329448DERIVEDHijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1582-90. doi: 10.1093/eurheartj/ehw054. Epub 2016 Feb 25.
PMID: 26920728DERIVEDVedin O, Hagstrom E, Budaj A, Denchev S, Harrington RA, Koenig W, Soffer J, Sritara P, Stebbins A, Stewart RH, Swart HP, Viigimaa M, Vinereanu D, Wallentin L, White HD, Held C; STABILITY Investigators. Tooth loss is independently associated with poor outcomes in stable coronary heart disease. Eur J Prev Cardiol. 2016 May;23(8):839-46. doi: 10.1177/2047487315621978. Epub 2015 Dec 16.
PMID: 26672609DERIVEDVedin O, Hagstrom E, Gallup D, Neely ML, Stewart R, Koenig W, Budaj A, Sritara P, Wallentin L, White HD, Held C. Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. Eur J Prev Cardiol. 2015 Jun;22(6):771-8. doi: 10.1177/2047487314530660. Epub 2014 Apr 10.
PMID: 24721691DERIVEDSTABILITY Investigators; White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, Lopez-Sendon J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30.
PMID: 24678955DERIVEDVedin O, Hagstrom E, Stewart R, Brown R, Krug-Gourley S, Davies R, Wallentin L, White H, Held C. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. Eur J Prev Cardiol. 2013 Aug;20(4):678-85. doi: 10.1177/2047487312444995. Epub 2012 Apr 10.
PMID: 22496275DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- GSK Response Center
- Organization
- GlaxoSmithKline
Study Officials
- STUDY DIRECTOR
GSK Clinical Trials
GlaxoSmithKline
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 26, 2008
First Posted
December 1, 2008
Study Start
December 1, 2008
Primary Completion
October 1, 2013
Study Completion
October 17, 2013
Last Updated
August 10, 2017
Results First Posted
August 10, 2017
Record last verified: 2017-03
Data Sharing
- IPD Sharing
- Will share
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.